ATE319479T1 - Verfahren zur erhöhen der bioverfügbarkeit und dem eindringen in gefässe von azithromycin - Google Patents
Verfahren zur erhöhen der bioverfügbarkeit und dem eindringen in gefässe von azithromycinInfo
- Publication number
- ATE319479T1 ATE319479T1 AT01301510T AT01301510T ATE319479T1 AT E319479 T1 ATE319479 T1 AT E319479T1 AT 01301510 T AT01301510 T AT 01301510T AT 01301510 T AT01301510 T AT 01301510T AT E319479 T1 ATE319479 T1 AT E319479T1
- Authority
- AT
- Austria
- Prior art keywords
- azithromycin
- increase bioavailability
- vessel penetration
- bioavailability
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18427300P | 2000-02-23 | 2000-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE319479T1 true ATE319479T1 (de) | 2006-03-15 |
Family
ID=22676248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01301510T ATE319479T1 (de) | 2000-02-23 | 2001-02-20 | Verfahren zur erhöhen der bioverfügbarkeit und dem eindringen in gefässe von azithromycin |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20020009433A1 (de) |
| EP (1) | EP1127580B1 (de) |
| JP (1) | JP2001261564A (de) |
| KR (1) | KR100522062B1 (de) |
| AT (1) | ATE319479T1 (de) |
| AU (1) | AU784100B2 (de) |
| CA (1) | CA2337616A1 (de) |
| DE (1) | DE60117716T2 (de) |
| DK (1) | DK1127580T3 (de) |
| ES (1) | ES2256168T3 (de) |
| HU (1) | HUP0100844A3 (de) |
| IL (1) | IL141438A0 (de) |
| NZ (1) | NZ536450A (de) |
| PT (1) | PT1127580E (de) |
| TW (1) | TWI289456B (de) |
| ZA (1) | ZA200101488B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20010301A2 (en) * | 2001-04-27 | 2001-12-31 | Pliva D D | New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases |
| ES2222093A1 (es) * | 2003-07-01 | 2005-01-16 | Advanced In Vitro Cell Technologies, S.L. | Metodo para el almacenamiento y/o transporte de cultivos celulares in vitro. |
| US20050013835A1 (en) * | 2003-07-15 | 2005-01-20 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
| EP1944042A1 (de) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Kombinationen für die HCV-Behandlung |
| KR20060092281A (ko) * | 2003-12-04 | 2006-08-22 | 화이자 프로덕츠 인크. | 액체 기초 방법에 의한 아지트로마이신 복합입자 투여형 |
| AU2004294817B2 (en) * | 2003-12-04 | 2007-01-25 | Pfizer Products Inc. | Method for making pharmaceutical multiparticulates |
| US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| CA2547597A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
| WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
| CA2549225A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| SG174146A1 (en) | 2009-02-27 | 2011-10-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
| RU2591830C2 (ru) | 2009-04-25 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Способы улучшения фармакокинетики |
| JP5639155B2 (ja) | 2009-05-13 | 2014-12-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | C型肝炎ウイルスインヒビターとしての大環状化合物 |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI8110592A8 (en) * | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| DE4120038A1 (de) * | 1991-06-18 | 1992-12-24 | Broadcast Television Syst | Steckverbinder fuer lichtwellenleiter |
| US5817321A (en) * | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
| EP0619730B1 (de) * | 1992-10-08 | 2000-12-27 | Supratek Pharma Inc. | Zusammensetzung von in mizellen eingeschlossenen antineoplastischen wirkstoffen |
| US5840319A (en) * | 1992-10-08 | 1998-11-24 | Alakhov; Valery Yu | Biological agent compositions |
| US6277410B1 (en) * | 1992-10-08 | 2001-08-21 | Supratek Pharma Inc. | Copolymer compositions for oral delivery |
| US6153193A (en) * | 1993-04-28 | 2000-11-28 | Supratek Pharma Inc. | Compositions for targeting biological agents |
| IN176897B (de) * | 1993-10-29 | 1996-09-28 | Cadila Lab Ltd | |
| US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| ATE209497T1 (de) * | 1994-05-06 | 2001-12-15 | Pfizer | Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe |
| US5891845A (en) * | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
| DK0925789T4 (da) * | 1997-12-02 | 2009-07-13 | Pfizer Prod Inc | Anvendelse af azithromycin ved topisk behandling af öjeninfektioner |
| CN1223116A (zh) * | 1998-01-14 | 1999-07-21 | 张志宏 | 防齐霉素肠溶制剂 |
| US6500459B1 (en) * | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
-
2001
- 2001-02-15 IL IL14143801A patent/IL141438A0/xx unknown
- 2001-02-19 TW TW090103717A patent/TWI289456B/zh not_active IP Right Cessation
- 2001-02-20 US US09/788,886 patent/US20020009433A1/en not_active Abandoned
- 2001-02-20 DE DE60117716T patent/DE60117716T2/de not_active Expired - Fee Related
- 2001-02-20 DK DK01301510T patent/DK1127580T3/da active
- 2001-02-20 ES ES01301510T patent/ES2256168T3/es not_active Expired - Lifetime
- 2001-02-20 PT PT01301510T patent/PT1127580E/pt unknown
- 2001-02-20 AT AT01301510T patent/ATE319479T1/de not_active IP Right Cessation
- 2001-02-20 EP EP01301510A patent/EP1127580B1/de not_active Expired - Lifetime
- 2001-02-21 CA CA002337616A patent/CA2337616A1/en not_active Abandoned
- 2001-02-22 AU AU23172/01A patent/AU784100B2/en not_active Ceased
- 2001-02-22 JP JP2001046540A patent/JP2001261564A/ja active Pending
- 2001-02-22 ZA ZA200101488A patent/ZA200101488B/xx unknown
- 2001-02-22 NZ NZ536450A patent/NZ536450A/xx unknown
- 2001-02-22 HU HU0100844A patent/HUP0100844A3/hu unknown
- 2001-02-23 KR KR10-2001-0009158A patent/KR100522062B1/ko not_active Expired - Fee Related
-
2003
- 2003-10-17 US US10/688,142 patent/US20040091527A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TWI289456B (en) | 2007-11-11 |
| US20040091527A1 (en) | 2004-05-13 |
| HUP0100844A3 (en) | 2002-04-29 |
| KR20010085503A (ko) | 2001-09-07 |
| ZA200101488B (en) | 2002-08-21 |
| ES2256168T3 (es) | 2006-07-16 |
| EP1127580A3 (de) | 2001-09-05 |
| US20020009433A1 (en) | 2002-01-24 |
| AU784100B2 (en) | 2006-02-02 |
| JP2001261564A (ja) | 2001-09-26 |
| PT1127580E (pt) | 2006-06-30 |
| DE60117716D1 (de) | 2006-05-04 |
| CA2337616A1 (en) | 2001-08-23 |
| DE60117716T2 (de) | 2006-09-21 |
| NZ536450A (en) | 2006-03-31 |
| HU0100844D0 (en) | 2001-04-28 |
| KR100522062B1 (ko) | 2005-10-18 |
| DK1127580T3 (da) | 2006-06-12 |
| AU2317201A (en) | 2001-08-30 |
| IL141438A0 (en) | 2002-03-10 |
| EP1127580B1 (de) | 2006-03-08 |
| EP1127580A2 (de) | 2001-08-29 |
| HUP0100844A2 (hu) | 2002-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE319479T1 (de) | Verfahren zur erhöhen der bioverfügbarkeit und dem eindringen in gefässe von azithromycin | |
| ATE515277T1 (de) | Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten | |
| DE60232464D1 (de) | Verfahren und zusammensetzung zur verbesserung der brenn- oder kraftstoffverbrennung | |
| EP1303299A4 (de) | Zusammensetzungen und methoden zur verstärkung der immunogenität von antigenen | |
| UA88463C2 (ru) | Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции | |
| AU2001245437A1 (en) | Lightweight methods and compositions for well treating | |
| BRPI0608376A8 (pt) | composição de ligação, método de uso de uma composição de ligação, e, kit de detecção | |
| EP2606933A3 (de) | Kombination eines IAP inhibitors und eines Taxanes | |
| DE60114294D1 (de) | Vorrichtungen und Verfahren zur Verstärkung von geschlossenen, konstruktiven Bauelementen | |
| EP2623105A3 (de) | Modulation von reversen LINE-1-Transkriptasen | |
| IL177793A0 (en) | Method and composition for burned skin | |
| EG23292A (en) | Textile finishing composition and methods for using same. | |
| HUP0400563A3 (en) | Method for producing an organic solvent-free lycopene concentrate, the resulting concentrate and composition comprising said concentrate | |
| MX246293B (es) | Composiciones y metodos para tratar hiperpigmentacion. | |
| MXPA03004499A (es) | Kit de repinotan. | |
| SG118236A1 (en) | Compositions and methods for treating coronavirus infection and SARS | |
| WO1999064001A3 (en) | Methods and compositions for increasing penetration of hiv protease inhibitors | |
| PL364570A1 (en) | Composition and method for controlled release injections | |
| DE60225579D1 (de) | Photochrome härtbare zusammensetzung mit hohen brechungindex und verfahren zu seiner herstellung | |
| AU2003251198A1 (en) | Composition comprising the extract of cistanche deserticola y.c. ma showing enhancing activity of the neurite outgrowth and neurotrophic effects | |
| ATE554740T1 (de) | Dentalzusammensetzungen mit geringer schwindung und geringer spannung | |
| AU2001270310A1 (en) | Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same | |
| MXPA04004075A (es) | Compuesto y metodo para tratamiento de vejiga hiperactiva. | |
| DE60230536D1 (de) | Zusammensetzung und verfahren | |
| DE502004007865D1 (de) | Verfahren zur herstellung bzw. bearbeitung von gasturbinenbauteilen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1127580 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |